)
Aura Biosciences (AURA) investor relations material
Aura Biosciences Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline overview and development strategy
Advancing a novel class of Virus-like Drug Conjugates with direct cytotoxicity and robust immune activation, targeting ocular oncology and bladder cancer as key areas of focus.
Ongoing phase III trial in early-stage choroidal melanoma, aiming for organ preservation and prevention of metastasis, with a unique frontline positioning and minimal competition.
Phase II and proof-of-concept studies in additional ocular indications (metastatic and ocular surface cancers) and bladder cancer, with multiple near-term catalysts expected.
Ocular oncology program details
Phase III trial (CoMpass) in early choroidal melanoma is enrolling patients with growing tumors to ensure a highly powered study and clear differentiation between treatment and sham.
Enrollment bottleneck due to need for tumor progression confirmation, but consistent patient conversion now supports guidance for study completion in 2026 and top-line data in Q4 2027.
Safety profile is favorable, with only Grade 1 local adverse events and no systemic exposure, supporting frontline use.
Secondary composite endpoint includes visual acuity preservation, designed with FDA input to strengthen the value proposition.
Proof-of-concept studies in metastatic and ocular surface cancers expected to support supplemental BLA filings with minimal additional data.
Bladder cancer program and market positioning
Focused on neoadjuvant treatment of early-stage tumors, leveraging the drug's mechanism that requires tumor presence for efficacy and immune activation.
No direct competitors in the neoadjuvant NMIBC space; most others are in adjuvant settings.
Using recurrence-free survival (RFS) as a validated endpoint, aiming to demonstrate improved outcomes with a highly tolerable, urologist-friendly formulation.
Neoadjuvant approach may complement, not replace, adjuvant therapies, with the sequence of therapy being a key differentiator.
Next Aura Biosciences earnings date
Next Aura Biosciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage